Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.

Asmuth, David M

Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. [electronic resource] - AIDS (London, England) Aug 2012 - 1625-34 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1473-5571

10.1097/QAD.0b013e3283546595 doi


Acquired Immunodeficiency Syndrome--drug therapy
Anti-HIV Agents--immunology
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes--drug effects
CD8-Positive T-Lymphocytes--drug effects
Drug Therapy, Combination
Endoscopy
Female
Gastrointestinal Tract--immunology
Humans
Immune Reconstitution Inflammatory Syndrome--chemically induced
Immunohistochemistry
Lymphocyte Activation
Lymphoid Tissue--immunology
Male
Nevirapine--therapeutic use
Nitriles
Pyridazines--therapeutic use
Pyrimidines
Pyrrolidinones--therapeutic use
RNA, Viral
Raltegravir Potassium
Reverse Transcriptase Inhibitors--therapeutic use
Viral Load